EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC 4.0

The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis

Hagar Cohen iD, Ghadeer Mahajna iD, Tomer Ben-Shushan iD, Ilan Matok iD, Sara Eyal iD

Epilepsia · 2024-02 · 65 (2) · 445-455

DOI: 10.1111/epi.17822 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift Epilepsia, online erschienen am 11.12.2023. Verfasst von Hagar Cohen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Carbamates, Chlorophenols, Cytochrome P-450 CYP3A, Phenytoin. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Antiseizure medications (ASMs) are commonly categorized as enzyme‐inducers and non‐enzyme‐inducers based on their propensity to enhance the metabolism of concomitantly administered drugs. This systematic review and network meta‐analysis aimed to rank ASMs as cytochrome P450 3A (CYP3A)‐inducers based on a comparative assessment of ASM‐induced reduction in the concentrations of sensitive substrate drugs.

Methods

The protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews; CRD42022335846), and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analysis) standards were followed. We searched MEDLINE, Embase, and Cochrane until March 14, 2023 without an initial date restriction. Data were additionally obtained via the US Food and Drug Administration database. Studies had to be prospective, with ASM monotherapy for ≥5 days. The primary parameter was the magnitude of change in the area under the concentration–time curve of CYP3A substrates following treatment with the ASM. The standardized mean difference (SMD) was used as the point estimate for the indirect comparisons between ASMs using the pairwise method. Bias risk was assessed using the PKclin tool.

Results

We identified 14 open‐label, fixed‐sequence studies with 370 participants. The effect size of 600 mg/day carbamazepine did not differ from those of 300 mg/day phenytoin (SMD = −.06, 95% confidence interval [CI] = −.18 to .07) and 200 mg/day cenobamate (SMD = −.11, 95% CI = −.26 to .04). Carbamazepine at 600 mg/day was the strongest CYP3A‐inducer ( P ‐score = .88), followed by carbamazepine 400 mg/day (.83), phenytoin 300 mg/day (.79), and cenobamate 200 mg/day (.73). Eslicarbazepine (800 mg/day) ranked higher than cenobamate 100 mg/day and oxcarbazepine 900 mg/day (.60, .39, and .37, respectively). Significance Despite the limited number of studies, our network meta‐analysis emphasizes that the magnitude of ASM effects on CYP3A substrate metabolism is a dose‐dependent continuum. When possible, ASM classification as inducers should apply cutoff values tailored to the outcome. Prescribers should monitor plasma concentrations or clinical effects of CYP3A substrates and consider selecting concomitant medications accordingly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbamatesChlorophenolsCytochrome P-450 CYP3APhenytoinTetrazolesHumansBenzodiazepinesCarbamazepinePharmaceutical Preparations

Stichwörter der Autor:innen

AUCCYP3A4antiepileptic drugsdrug interactionssystematic review and meta-analysis

Substanzen

BenzodiazepinesCarbamatesCarbamazepineCenobamateChlorophenolsCytochrome P-450 CYP3APharmaceutical PreparationsPhenytoinTetrazoles

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Faculty of Medicine, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Medical Library Authority, Hebrew University of Jerusalem, Jerusalem, Israel.

ORCID-Profile: Hagar Cohen, Ghadeer Mahajna, Tomer Ben-Shushan, Ilan Matok, Sara Eyal

Zitieren

APA

Cohen, H., Mahajna, G., Ben-Shushan, T., Matok, I., & Eyal, S. (2024). The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis. Epilepsia, 65(2), 445-455. https://doi.org/10.1111/epi.17822

Vancouver

Cohen H, Mahajna G, Ben-Shushan T, Matok I, Eyal S. The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis. Epilepsia. 2024;65(2):445-455. doi:10.1111/epi.17822

BibTeX
@article{Cohen2024,
  author = {Cohen, Hagar and Mahajna, Ghadeer and Ben-Shushan, Tomer and Matok, Ilan and Eyal, Sara},
  title = {The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis},
  journal = {Epilepsia},
  year = {2024},
  volume = {65},
  number = {2},
  pages = {445--455},
  doi = {10.1111/epi.17822}
}
Kostenlos starten →